[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.129.152. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
October 1992

Systemic Interferon Gamma as Adjuvant Therapy for Refractory Anogenital Warts: A Randomized Clinical Trial and Meta-analysis of the Available Data

Author Affiliations

Department of Dermatology University Medical Center Steglitz The Free University of Berlin Hindenburgdamm 30 W-1000 Berlin 45, Germany; Institute for Medical Statistics and Informatics University Medical Center Steglitz The Free University of Berlin Hindenburgdamm 30 W-1000 Berlin 45, Germany; Department of Dermatology University Medical Center Steglitz The Free University of Berlin Hindenburgdamm 30 W-1000 Berlin 45, Germany

Arch Dermatol. 1992;128(10):1413-1414. doi:10.1001/archderm.1992.01680200125033
Abstract

To the Editor.—  Antiviral, antiproliferative, and immunomodulating properties make interferons a logical therapeutic approach for anogenital warts. Unlike type I interferons, which have been applied for treatment of anogenital warts in large studies,1 only a few patients, so far, have been treated with systemically administered recombinant interferon gamma.2-5The present study was designed to investigate the efficacy of adjuvant systemic recombinant interferon gamma on the cure rate of surgically removed refractory anogenital warts.

Patients and Methods.—  Twenty patients (16 men and four women; median age, 27 years; age range, 19 to 60 years) suffering from refractory anogenital warts were enrolled in the study between May 1988 and January 1989. Patients had to fulfill the following criteria: multiple visible lesions, age between 18 and 65 years, good general health, disease duration of at least 1 year, failure of at least one traditional treatment, histologic confirmation of the diagnosis,

First Page Preview View Large
First page PDF preview
First page PDF preview
×